GlassScriptPhysician profile
Alexandra Martin
NPI 1730340787
$3,071.14
in general payments reported to CMS, 2019-2025
36 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $130 · 2021: $454 · 2022: $483 · 2023: $677 · 2024: $700 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,805.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $591.15 | 2019-2025 | |
| Abbott Laboratories | $213.01 | 2019-2025 | Freestyle Libre 3 |
| Ultragenyx Pharmaceutical INC. | $201.64 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $195.49 | 2024 | |
| Insulet Corporation | $190.89 | 2019-2025 | Omnipod |
| Medtronic, INC. | $180.71 | 2024 | Minimed 780g |
| Pfizer INC. | $130.76 | 2019-2025 | |
| Eton Pharmaceuticals, INC. | $128.85 | 2021-2025 | Alkindi, Increlex, Khindivi |
| Azurity Pharmaceuticals, INC. | $124.11 | 2022-2025 | Triptodur, Triptodur |
| Ascendis Pharma Endocrinology INC | $121.56 | 2022-2025 | Skytrofa |
| Xeris Pharmaceuticals, INC. | $113.67 | 2020-2024 | Gvoke Hypopen |
| Biomarin Pharmaceutical INC. | $70.43 | 2019-2023 | Voxzogo 1.2mg |
| Regeneron Healthcare Solutions, INC. | $68.84 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $57.10 | 2020-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Endo Pharmaceuticals INC. | $56.65 | 2022-2024 | Supprelin |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $48.72 | 2025 | |
| Boston Scientific Corporation | $48.43 | 2022 | |
| Zealand Pharma US, INC. | $44.16 | 2021 | |
| Endo USA, INC. | $42.81 | 2024-2025 | Supprelin |
| Arbor Pharmaceuticals, INC. | $42.67 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $38.18 | 2023-2025 | Strensiq |
| Ferring Pharmaceuticals INC. | $36.97 | 2019-2020 | |
| Dexcom, INC. | $32.74 | 2024 | Dexcom G6 Transmitter |
| Rhythm Pharmaceuticals, INC. | $31.45 | 2022-2024 | Imcivree |
| Neurocrine Biosciences, INC. | $30.76 | 2025 | |
| Ani Pharmaceuticals, INC. | $30.34 | 2024 | Purified Cortrophin Gel |
| Leadiant Biosciences, INC. | $29.50 | 2023 | Cystaran |
| Lilly USA, LLC | $28.67 | 2019-2021 | |
| Beta Bionics, INC. | $23.82 | 2023 | Ilet Bionic Pancreas |
| Novo Nordisk INC | $23.38 | 2022 | |
| Amneal Pharmaceuticals LLC | $23.06 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $19.35 | 2022 | |
| Ibsa Pharma INC. | $18.20 | 2025 | Flector, Licart, Tirosint |
| Astrazeneca Pharmaceuticals LP | $16.80 | 2022 | |
| Soleno Therapeutics, INC. | $16.27 | 2025 | Vykat Xr |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.